NCT05464940
Impact of Intravenous Caffeine on Atrial Electrical Properties and Potential Arrythmia Induction
StatusUnknown
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
- Notable Primary completion date: Jun 2025 to Mar 2026
- Start date: Dec 2024 to Sep 2025
- Study completion date: Sep 2025 to Jun 2026
- Notable Primary completion date: Dec 2023 to Jun 2025
- Start date: Jun 2023 to Dec 2024
- Study completion date: Dec 2023 to Sep 2025
- Notable Start date: Jan 2023 to Jun 2023
- Primary completion date: Aug 2023 to Dec 2023
- Notable Start date: Aug 2022 to Jan 2023v3
- Minor Secondary endpoints revised (4)
- Study description expanded, about 4 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants With Atrial Fibrillation Induction
Timeframe: 1 day
Secondary (4)
Number of patients with Site-specific changes in AERP(Atrial Effective Refractory Period)
Number of patients with Changes in conduction time
Number of patients with Induction of Atrial Fibrillation/Atrial Tachycardia (AF/AT) or other arrhythmias
Number of patients with Identification of non-pulmonary triggers of AF
Arms and interventions
Group assigned to receive caffeineActive comparator
Group assigned to receive masked placeboPlacebo comparator
Other: Intravenous caffeine, Masked Placebo
Sites
9 sites in 1 country